Comparison of CASI Pharmaceuticals Inc. (CASI) and Athenex Inc. (NASDAQ:ATNX)

CASI Pharmaceuticals Inc. (NASDAQ:CASI) and Athenex Inc. (NASDAQ:ATNX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CASI Pharmaceuticals Inc. 3 0.00 N/A -0.35 0.00
Athenex Inc. 14 13.14 N/A -2.21 0.00

Table 1 highlights CASI Pharmaceuticals Inc. and Athenex Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of CASI Pharmaceuticals Inc. and Athenex Inc.

Net Margins Return on Equity Return on Assets
CASI Pharmaceuticals Inc. 0.00% -31.2% -28.3%
Athenex Inc. 0.00% -109.1% -66.6%

Liquidity

The current Quick Ratio of CASI Pharmaceuticals Inc. is 21.5 while its Current Ratio is 21.5. Meanwhile, Athenex Inc. has a Current Ratio of 2.2 while its Quick Ratio is 1.9. CASI Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Athenex Inc.

Analyst Recommendations

The table shown features the ratings and recommendations for CASI Pharmaceuticals Inc. and Athenex Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CASI Pharmaceuticals Inc. 0 0 0 0.00
Athenex Inc. 0 0 1 3.00

Meanwhile, Athenex Inc.’s consensus target price is $20, while its potential upside is 34.95%.

Institutional & Insider Ownership

Institutional investors owned 21% of CASI Pharmaceuticals Inc. shares and 33.3% of Athenex Inc. shares. About 41.36% of CASI Pharmaceuticals Inc.’s share are owned by insiders. Insiders Competitively, owned 8.6% of Athenex Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CASI Pharmaceuticals Inc. -2.19% 1.3% -2.5% -11.86% -55.74% -22.39%
Athenex Inc. -5.26% -5.31% 90.68% 58.73% -3.95% 41.84%

For the past year CASI Pharmaceuticals Inc. has -22.39% weaker performance while Athenex Inc. has 41.84% stronger performance.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.